MyFinsight
Home
Blog
About
VOXZOGO
$252,528K
(14.06%↑ Y/Y)
VIMIZIM
$194,371K
(-9.77%↓ Y/Y)
NAGLAZYME
$135,255K
(4.96%↑ Y/Y)
PALYNZIQ
$135,167K
(27.59%↑ Y/Y)
GALAFOLD
$105,748K
BRINEURA
$51,370K
(5.50%↑ Y/Y)
ALDURAZYME
$43,539K
(-22.85%↓ Y/Y)
POMBILITIOPFOLDA
$30,258K
KUVAN
$24,444K
(-9.58%↓ Y/Y)
ROCTAVIAN
$11,713K
(27.33%↑ Y/Y)
Product
$984,393K
(21.08%↑ Y/Y)
Royalty And Other
$5,315K
(-57.23%↓ Y/Y)
Total revenues
$989,708K
(19.91%↑ Y/Y)
Income from operations
$110,920K
(-59.94%↓ Y/Y)
Interest income
$10,480K
(-44.34%↓ Y/Y)
Other income, net
$3,279K
(-32.15%↓ Y/Y)
Total operating
expenses
$878,788K
(60.21%↑ Y/Y)
Income before income
taxes
$61,384K
(-79.39%↓ Y/Y)
Interest expense
$63,295K
(2262.64%↑ Y/Y)
Selling, general and
administrative
$395,549K
(70.29%↑ Y/Y)
Research and development
$206,952K
(28.30%↑ Y/Y)
Cost of sales
$202,795K
(35.12%↑ Y/Y)
Intangible asset
amortization
$73,492K
(1416.55%↑ Y/Y)
Net income
$44,762K
(-81.39%↓ Y/Y)
Provision for income taxes
$16,622K
(-71.01%↓ Y/Y)
Back
Back
Income Statement
biomarin-logo-svg
source: myfinsight.com
BIOMARIN PHARMACEUTICAL INC (BMRN)
biomarin-logo-svg
BIOMARIN PHARMACEUTICAL INC (BMRN)